This Molecule Just Rewired Cancer’s Own Engine to Destroy Itself

In mice implanted with human diffuse large B-cell lymphoma tumors, twice-daily administration of the experimental molecule TCIP3 led to complete tumor disappearance within 11 days. No toxicity or elevated inflammatory signals were observed in treated animals, despite elimination of germinal centers — immune cell clusters dependent on BCL6 activity.

How TCIP3 repurposes a cancer driver

BCL6 is a transcription factor frequently overactive in diffuse large B-cell lymphoma, the most common form of non-Hodgkin lymphoma. In healthy immune cells, BCL6 temporarily suppresses genes involved in growth arrest and apoptosis during immune responses; once the threat resolves, other proteins modify and deactivate it, allowing programmed cell death to proceed. In lymphoma, however, BCL6 remains constitutively active, continuously silencing death-promoting genes and enabling uncontrolled proliferation.

Rather than merely inhibiting BCL6, Stanford Medicine scientists engineered TCIP3 to physically link BCL6 with lysine acetyltransferases P300 and CBP. One end of TCIP3 binds BCL6; the other binds either P300 or CBP. These enzymes then add acetyl marks to BCL6 itself — disabling its gene-suppressing function — and to histones, loosening chromatin structure to permit transcription factor access and activation of downstream cell death genes.

Molecular glue enhances complex stability

X-ray crystallography revealed an unexpected structural feature: once TCIP3 brought BCL6 and P300/CBP into proximity, additional non-covalent interactions formed between the proteins, reinforcing the ternary complex. Researchers characterized TCIP3 as a “molecular glue” that stabilizes otherwise transient associations. Structural insights enabled chemical optimization — increasing rigidity between TCIP3’s two functional domains — which preserved productive protein–protein contacts and improved potency. The refined compound killed cultured lymphoma cells at very low concentrations.

Broader therapeutic implications

The study’s lead authors are graduate student Meredith Nix and postdoctoral scholar Sai Gourisankar, PhD. Senior authors include Gerald Crabtree, MD, the David Korn, MD, Professor in Pathology and professor of developmental biology; Nathanael Gray, PhD, the Krishnan-Shah Family Professor and professor of chemical and systems biology; Stephen Hinshaw, PhD, assistant professor of molecular and cellular physiology; and Michael Green, PhD, director of translational and laboratory research, lymphoma/myeloma at the MD Anderson Cancer Center. Their work appeared in Cell on 20 July 2026.

Because germinal center B cells — whose survival depends on BCL6 — also drive certain autoimmune conditions such as rheumatoid arthritis and myasthenia gravis, the researchers propose that TCIP3-like molecules may hold therapeutic potential beyond oncology. However, TCIP3 itself requires further chemical refinement and evaluation in additional animal species before clinical trials can be considered. The underlying strategy — using bivalent molecules to redirect, rather than inhibit, disease-driving transcription factors — is being explored for other targets implicated in cancer and autoimmunity.

“We’re trying to essentially fight cancer with its cause — taking the driving force of the cancer and then rewiring it to activate cell death mechanisms,” said Crabtree.

“This could be a powerful approach to tackling other cell death repressors or transcription factors that control genes we want to activate in cancer,” Nix added.

The study was funded by the National Institutes of Health (grants CA276167, CA163915, R01CA3044298, MH126720-01, S10OD028697-01, R01CA201380 and 1K99CA296700-01), the Howard Hughes Medical Institute, the Mary Kay Foundation, the Williams Foundation, the Victor Family Fund, Ed and Beatriz Schweitzer, the David L. Sze and Kathleen Donahue Interdisciplinary Fellowship, and a PhRMA Foundation Predoctoral Fellowship in Drug Discovery.